Traphaco holds kick-off ceremony for manufacturing phase 2 technology transfer products

Traphaco welcomes Daewoong's leaders and staffs to the kick-off ceremony.

Marking 50 years of establishment and development, Traphaco's strategy in the new phase has also been reoriented to both maintain our No. 1 position in the field of herbal medicine and strongly shift to developing high-quality Western medicine. Speaking at the event, Mr. Tran Tuc Ma, CEO of Traphaco, shared about this strategy of the company. Traphaco has established Technology Transfer Department and Western Medicine Research & Development Departments separately, focusing on Bioequivalent and first generic drugs, while planning to invest in building a GMP-EU standard factory. Mr. Ma emphasized that technology transfer is one of the key tasks according to the Resolution of the General Meeting of Shareholders for the period 2021-2025. The products transferred from Daewoong not only enhance the value of the Western medicine group but also realize Traphaco's strategy of building a high-quality Western medicine brand.

Mr. Tran Tuc Ma – Chief Executive Officer of Traphaco and Mr. Cha Jun Woo - Head of Global Business Development at Daewoong speaking at the ceremony.

Meanwhile, Mr. Cha Jun Woo, Head of Global Business Development at Daewoong, expressed great expectations for this technology transfer. He said that the products in phase 2 will not only stop at single-ingredient generic drugs but also include combination drugs, serving the treatment of chronic diseases such as diabetes, cardiovascular diseases, and dyslipidemia. To ensure the effective implementation of technology transfer, Daewoong has sent four experienced experts to Traphaco Hung Yen for direct support. He also revealed that in phase 3, the product portfolio will expand with advanced dosage forms such as suspensions, sustained-release tablets, and multi-layered tablets used in the treatment of digestive diseases, hypertension, and cardiovascular diseases, especially the appearance of key products that have affirmed Daewoong's position in the Korean market. This close cooperation not only reflects Daewoong's commitment but also helps Traphaco improve production capacity and meet the increasing demands of the Vietnamese market.

The kick-off ceremony for the research and registration process of the phase 2 technology transfer project took place during the Covid-19 pandemic.

The implementation of technology transfer cooperation between Traphaco and Daewoong from the early years has faced many challenges, especially in the context of the Covid-19 pandemic. During this period, although working mainly through online, the two sides made efforts to complete the registration procedures for phase 1 technology transfer products and coordinate the selection of products for phase 2. In early 2022, to promote business and market access, Traphaco took a strategic step by separating the sales teams for herbal medicine and non-herbal medicine. This helps to focus specialized resources on the Western medicine group, including technology transfer products from Daewoong.

Activities to introduce and promote DW-TRA TimaRo, DW-TRA RebaTot, and Acid Ursodeoxycholic, which belong to Traphaco's technology transfer product line

Throughout 2023, Traphaco organized a series of product introduction activities. Phase 1 technology transfer products have been introduced to more than 3,000 major pharmacies nationwide, through scientific conferences, specialized seminars at hospitals, and direct presentations to doctors and pharmacists. These events both promote the product and affirm Traphaco's outstanding ability to manufacture and develop Western medicines that meet bioequivalence standards.

Traphaco's Chief Operating Officer, Mrs. Dao Thuy Ha, summarizes the 5-year journey of implementing phase 1 of the project between Daewoong and Traphaco..

Mrs. Dao Thuy Ha – COO of Traphaco shared that the phase 1 technology transfer products have all caught up with market trends, with revenue increasing by more than 1.5 times over the same period last year. The high appreciation from pharmacies and doctors for the quality and reasonable price of the product has confirmed that Traphaco's direction in technology transfer and Western medicine development is completely correct, opening up great prospects for phase 2, when new products promise to continue to bring sustainable values to the company and the community.

Mr. Tran Tuc Ma and Mr. Cha Jun Woo officially kick off the production and market launch of the phase 2 technology transfer project between the two parties.

The kick-off ceremony not only marks the strong cooperation between Traphaco and Daewoong but also opens up a new and promising phase. The deployment of manufacturing phase 2 technology transfer products continues to affirm Traphaco's commitment in bringing high-quality Western medicines to meet the healthcare needs of the community. At the same time, this is also clear evidence of Traphaco's sustainable and innovative development strategy in the journey to affirm our leading position in pharmaceutical industry of Vietnam.

The ceremony was attended by Mr. Panem Vamsi Krishna - Senior Formulation Research Expert at Daewoong.

Speech by Traphaco's Chief Executive Officer, Mr. Tran Tuc Ma.

Speech by Daewoong's representative, Mr. Cha Jun Woo.

Speech by Mrs. Dao Thuy Ha – Chief Operating Officer of Traphaco.

Mr. Oh Tae Won - Head of Formulation Research at Daewoong speaking at the ceremony.

Mr. Kim Dong Hyu – Executive Vice CEO of Traphaco speaking at the ceremony.

The kick-off ceremony not only marks the strong cooperation between Traphaco and Daewoong but also opens up a new and promising phase.